This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
With shares of Iovance Biotherapeutics (NASDAQ: IOVA) soaring by 175% in the last three months, Wells Fargo analyst Yanan Zhu thinks they could still go as much as 47% higher. In fact, on Feb. 20, the analyst raised his price target for the stock from $17 to $22. Yanan wasn’t alo
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-722208811-b3d22c5e5c164942a1983f328bfe06be.jpg "How to Become a Retirement Super Saver")